Freenome (FRNM) vs YD Bio (YDES)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Freenome (FRNM) has outperformed YD Bio (YDES) over the past year, gaining 48.9% versus a loss of 64.0%. Freenome is the larger company by market cap ($1.70 billion vs $476.7 million), about 3.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FRNM | YDES |
|---|---|---|
| Share price | $15.78 | $6.73 |
| Market cap | $1.70B | $476.69M |
| 1-day change | -0.19% | +16.23% |
| YTD return | +21.11% | -44.79% |
| 1-year return | +48.87% | -64.03% |
| EPS (TTM) | $-2.03 | $-0.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $837.47K | — |
| 52-week high | $17.50 | $22.00 |
| 52-week low | $9.95 | $1.70 |
| Distance from 52-week high | -9.83% | -69.41% |
| Analyst consensus | none | — |
| Avg. price target upside | +14.07% | — |
| Average volume | 806.13K | 284.92K |
| Shares outstanding | 107.45M | 70.83M |
| Employees | 375 | 13 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Freenome is about 3.6 times larger than YD Bio by market value ($1.70B vs $476.69M).
- FRNM has outperformed YDES by 112.9 percentage points over the past year.
About Freenome
FRNM stock →Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer.
Health Care · Medical Specialities · 375 employees
About YD Bio
YDES stock →YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Health Care · Medical Specialities · 13 employees
FRNM vs YDES FAQ
Which is bigger, Freenome or YD Bio?
Freenome (FRNM) is larger, with a market capitalization of $1.70B compared with $476.69M for YD Bio (YDES).
Which stock has performed better over the past year, FRNM or YDES?
FRNM returned +48.87% over the past 12 months, compared with -64.03% for YDES (price return, excluding dividends). Past performance does not predict future results.
Are Freenome and YD Bio in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.